Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Salivary gland cancer
Stage/Subtype:  stage IV salivary gland cancer
Trial Type:  Treatment
Results 1-25 of 65 for your search:
Start Over
Radiation Therapy with or without Chemotherapy in Treating Patients with High-Risk Malignant Salivary Gland Tumors That Have Been Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1008, NCI-2013-00370, CDR0000686072, NCI-2011-00795, NCT01220583
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-1216, NCI-2013-00500, NCT01810913
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D4193C00002, NCI-2015-01842, NCT02369874
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Cisplatin with or without WEE1 Inhibitor MK-1775 in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: PHL-088, NCI-2014-00759, NCI 9416, NCT01935037, 9416, NCT02196168
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RXDX-101-02, NCI-2015-01848, NCT02568267
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Nivolumab with Image Guided, Stereotactic Body Radiation Therapy or Nivolumab Alone in Treating Patients with Metastatic Head and Neck Squamous Cell Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-253, NCI-2016-00261, NCT02684253
Enzalutamide in Treating Patients with Androgen Receptor Positive Locally Advanced or Metastatic Salivary Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A091404, NCI-2015-01706, NCT02749903
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients with Spine Metastases at Risk for Compressing the Spinal Cord
Status: Not yet active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: 2015-0223, NCI-2016-00683, NCT02713269
Axitinib in Treating Patients with Recurrent or Metastatic Head and Neck Cancer That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2016.040, NCI-2016-01064, NCT02762513
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA209-714, NCI-2016-01106, 2016-001645-64, NCT02823574
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Dose-escalation Study of Oral CX-4945
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-078, NCI-2011-02511, CDR0000689900, NCT01249443
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
Start Over